OBJECTIVE: There has been much interest in the use of atypical antipsychotics in anorexia nervosa (AN). However, newer, more weight-neutral medications have not been studied in AN, and there are no reports of the use of antipsychotics in bulimia nervosa (BN). METHOD: We report on the treatment of eight patients (five with AN and three with BN) with aripiprazole for time periods of four months to more than three years. RESULTS: All individuals had reduced distress around eating, fewer obsessional thoughts about food, weight and body image, significant lessening of eating-disordered behaviors, and gradual weight restoration where appropriate. Depression, generalized anxiety, and cognitive flexibility improved as well. DISCUSSION: In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN.
OBJECTIVE: There has been much interest in the use of atypical antipsychotics in anorexia nervosa (AN). However, newer, more weight-neutral medications have not been studied in AN, and there are no reports of the use of antipsychotics in bulimia nervosa (BN). METHOD: We report on the treatment of eight patients (five with AN and three with BN) with aripiprazole for time periods of four months to more than three years. RESULTS: All individuals had reduced distress around eating, fewer obsessional thoughts about food, weight and body image, significant lessening of eating-disordered behaviors, and gradual weight restoration where appropriate. Depression, generalized anxiety, and cognitive flexibility improved as well. DISCUSSION: In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN.
Authors: Guido K W Frank; Megan E Shott; Jennifer O Hagman; Marissa A Schiel; Marisa C DeGuzman; Brogan Rossi Journal: Int J Eat Disord Date: 2017-03-23 Impact factor: 4.861
Authors: Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-08-05 Impact factor: 8.829
Authors: Guido K W Frank; Jeremy R Reynolds; Megan E Shott; Leah Jappe; Tony T Yang; Jason R Tregellas; Randall C O'Reilly Journal: Neuropsychopharmacology Date: 2012-05-02 Impact factor: 7.853